The current financial score of Century Therapeutics Inc is 8.26. Its financial status is stable, and its operating efficiency is high.
The current valuation score of Century Therapeutics Inc is 6.14. Its current P/E ratio is -1.52, which is -79.02% below the recent high of -0.32 and -1446.48% above the recent low of -23.49.
The current earnings forecast score of Century Therapeutics Inc is 7.67. The average price target is 5.12, with a high of 8.00 and a low of 2.00.
The current price momentum score of Century Therapeutics Inc is 4.49. Currently, the stock price is trading between the resistance level at 2.06 and the support level at 1.50, making it suitable for range-bound swing trading.
The current institutional shareholding score of Century Therapeutics Inc is 5.00. The latest institutional shareholding proportion is 63.28%, representing a quarter-over-quarter increase of 64.36%. The largest institutional shareholder is James Simons, holding a total of 1.26M shares, representing 0.00% of shares outstanding, with 396.84% increase in holdings.
The current risk assessment score of Century Therapeutics Inc is 3.65. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.